admin
Admin
posted on
Iovance Therapeutics (IOVA) is down 6% in after-hours trading after its Q2 2022 financial results missed on the bottom line.
Iovance Biotherapeutics falls 6% on Q2 2022 bottom line missAug. 04, 2022 7:19 PM ETIovance Biotherapeutics, Inc. (IOVA)By: Jonathan Block, SA News Editor
Comments
0 comment